Report

GNMX: Details of New Gene-Subset ADHD Study. Top-Line Data Mid-2018

Underlying
Aevi Genomic Medicine Inc

Aevi Genomic Medicine is a clinical stage biopharmaceutical company with a focus on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. The company's product pipeline includes: AEVI-002, which is an anti-LIGHT monoclonal antibody that is in development for use in Pediatric Onset Crohn's disease; and AEVI-005, which is the monoclonal antibody the company is developing as part of its ongoing collaboration with Kyowa Hakko Kirin Co., Ltd. whereby the company is studying it in an undisclosed ultra-orphan auto-immune pediatric disease.

Provider
Zacks
Zacks

​Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch